PASSReviewer 1· 95% conf
The paper establishes a strong scientific premise with extensive prior work and a clear rationale for the study hypothesis.
Evidence
direct quote[Introduction, paragraphs 1-3]
“Loss of BRCA was first shown to sensitize cancers to inhibition of PARP via a process known as synthetic lethality”direct quote[Introduction, paragraph 3]
“We therefore aimed to evaluate whether the combination of PARP inhibition and an androgen receptor pathway inhibitor at response to first-line androgen deprivation (castration-sensitive prostate cancer) would be effective.”paraphrase[Introduction, paragraph 2]
“Despite the efficacy ... resistance commonly occurs, often after emergence of secondary alterations in BRCA2 that restore HRR function”PASSReviewer 2· 95% conf
The paper establishes a strong scientific premise by citing prior work on PARP inhibition, HRR alterations, and the rationale for combining PARP and androgen receptor pathway inhibitors in mCSPC.
Evidence
direct quote[Introduction, paragraphs 1-3]
“Despite the efficacy (improvements in both radiographic progression-free survival and overall survival) reported for PARP inhibitor monotherapy in mCRPC ,, , resistance commonly occurs, often after emergence of secondary alterations in BRCA2 that restore HRR function , .”direct quote[Introduction, paragraph 3]
“We therefore aimed to evaluate whether the combination of PARP inhibition and an androgen receptor pathway inhibitor at response to first-line androgen deprivation (castration-sensitive prostate cancer) would be effective.”direct quote[Introduction, paragraph 2]
“The relatively low prevalence of individual gene alterations and the heterogeneity of biological sensitization can make interpretation of single-gene groups within individual trials challenging”